The Life Sciences Report, by Streetwise Reports, is the leading source of investment coverage of Biotech, Pharmaceuticals, Medical Devices, Tools & Diagnostics.
Joined December 2011
- Tweets 5,244
- Following 514
- Followers 10,373
- Likes 146
1,632 Photos and videos
Teva Pharmaceutical Advances Neuroscience Pipeline With Strong AUSTEDO Growth and New Acquisition
ow.ly/z1qp50Zel0N
Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors.
$TEVA $APTX.TO
44
A New Pharma Giant Goes Public as a Sector Leader Makes Moves in Neuroscience
ow.ly/Cu9Q50Ze1tW
Apotex Health Corp. ( $APTX.TO ) raised approximately CA$1.3 billion in its IPO while Teva Pharmaceutical Industries Ltd. ( $TEVA ) reported new AUSTEDO data and added a late-stage Tourette syndrome asset.
168
Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies
ow.ly/9II950ZcV80
Explore how the pending GSK acquisition of Nuvalent at a premium underscores sector momentum in precision oncology, with key pipeline catalysts and market trends for retail investors to consider.
$NUVL
105
Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal
ow.ly/epYB50ZcPIN
Analysts downgrade Nuvalent Inc ( $NUVL ) to "Neutral" after GSK's US$10.6B all-cash buyout offer at US$124/share, calling the deal favorable but a competing bid unlikely.
85
Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment
ow.ly/rWFm50ZcntE
Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market.
$OCS
79
MindBio Therapeutics Positions Voice AI Kiosks for Growth in Workplace Safety Markets
ow.ly/5UVh50Zc1JN
MindBio Therapeutics advances prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, targeting high-growth opportunities in mining, aviation, and construction sectors amid expanding biotech and AI markets.
$MBIO.CN $MBQIF @MindBioTherap
81
MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors
ow.ly/8C7K50ZbV6U
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets.
$MBIO.CN $MBQIF @MindBioTherap
1
68
Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results
ow.ly/7AEF50ZbUXu
Oculis Holding AG ( $OCS ) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients.
86
MindBio Therapeutics Advances AI Voice Tech for Workplace Safety in Growing Biotech and AI Detector Markets
ow.ly/gfVf50ZbktV
MindBio Therapeutics delivers first prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, positioning the company in high-growth sectors including mining, aviation, and construction, while analysts highlight significant upside potential.
$MBIO.CN $MBQIF @MindBioTherap
77
Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity
ow.ly/SGr650ZaIUx
MindBio Therapeutics Corp. ( $MBIO.CN $MBQIF ) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market.
@MindBioTherap
78
Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market
ow.ly/In5w50Zaawh
Grey Matters Health advances its Alzheimer's neuroimaging strategy with fresh financing and plans for the first U.S. brain-specific PET clinic, capitalizing on rising demand for early detection tools.
$GREY.CN $AGNPF
116
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market
ow.ly/507z50Z9YS2
Explore how ORIC Pharmaceuticals is advancing its oncology pipeline with key catalysts ahead, amid rising global demand for innovative cancer treatments and strong analyst support.
$ORIC
54
Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close
ow.ly/wVZN50Z9H2r
Grey Matters Health Inc. ( $GREY.CN $AGNPF ) closed the first CA$500,000 tranche of a financing that the company said will support its Alzheimer's disease program and planned U.S. brain-specific neuroimaging clinic.
1
86
Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth
ow.ly/PQub50Z9vM0
ORIC Pharmaceuticals Inc. ( $ORIC ) granted 34,800 stock options and 5,900 restricted stock units to new employees as analysts issue "Buy" ratings for the year ahead.
166
Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses
ow.ly/cAzK50Z8hbt
Rakovina Therapeutics ( $RKV.V ) reported lower net losses, reduced administrative spending, debt restructuring, financing activity, and progress across its AI-driven oncology pipeline in Q1 2026.
117
From Healthcare IT Vendor to AI-Driven Holding Company
ow.ly/qI6t50Z89g6
Healthcare Triangle Inc.'s ( $HCTI ) Spanish AI acquisition delivers US$34M in revenue and a near-US$40M agentic AI run rate, while shares still trade at just 1x cash.
176
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%
ow.ly/Y8C250Z7Jrn
Revolution Medicines Inc.'s ( $RVMD ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a "Buy" with targets up to US$263.
307
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug
ow.ly/nAqq50Z6MmP
Capricor Therapeutics Inc.'s ( $CAPR ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60.
1
2
657
New Alzheimer's Imaging Push Expands as Financing Terms Get Investor-Friendly
ow.ly/mHpo50Z5I24
Grey Matters Health Inc. ( $GREY.CN $AGNPF ) amended warrant terms tied to its CA$1 million private placement as it advances plans for a U.S. brain-specific neuroimaging clinic focused on Alzheimer's diagnostics.
2
121
Biopharma Company Reveals High-Impact SCI Recovery Gains
ow.ly/siFE50Z5hbW
NervGen Pharma Corp. ( $NGEN.V $NGENF ) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs.
1
461